Skip to main navigation Skip to main content
The University of Southampton
News

International trial of innovative vaccine treatment for bowel cancer opens in Australia

Published: 2025-06-04 17:23:00
A close up of a syringe being filled from a vial of vaccine

An international trial which is exploring a new vaccine to treat patients with bowel cancer has begun recruiting patients in Australia.

The Neo-POLEM trial is exploring whether a vaccine that stimulates the patient’s immune system to attack cancer cells can improve treatment, quality of life and survival outcomes.

The trial is led by Dr Tony Dhillon at the Royal Surrey Hospital NHS Foundation Trust and the Cancer Research UK Southampton Clinical Trials Unit at the University of Southampton in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG). It is funded by immuno-oncology company, Imugene Limited.

The trial will recruit 44 patients across hospitals in Australia and the UK, with the first site now open at the Queen Elizabeth Hospital in South Australia.

Bowel cancer is the 4th most common cancer in the UK and Australia. Over 44,000 people are diagnosed with the disease in the UK each year.

In early stages, it is best treated with surgery and chemotherapy. However, around half of patients will see their cancer return, at which stage it is often incurable. New and more effective treatments are therefore urgently needed to improve outcomes for people facing this disease.

Evidence has previously shown that a vaccine called PD1-Vaxx has positive results for patients with lung cancer and the Neo-POLEM trial aims to build on these to see if it can work similarly well for certain people bowel cancer.

Around one in seven bowel cancer patients have mutation called defective mismatch repair (dMMR), where abnormal cells cannot be repaired, leading to tumour growth. It is thought these patients could be particularly sensitive to this type of vaccine.

The hope is that those who respond positively could be spared from having chemotherapy after surgery to remove any residual tumour, meaning fewer side effects from their cancer treatment.

Professor Tim Price, who is leading the Neo-POLEM trial in Australia, said: “We already know that intravenous antibodies can shrink colorectal cancers before they are removed, but Neo-POLEM will allow a simpler vaccine method of delivery and could preclude the need for chemotherapy after surgery.”

“To lead this trial in Australia is exciting. The results have the potential to make changes to international protocols.”

Professor Gareth Griffiths, Director of Southampton Clinical Trials Unit, said: “We have a particular interest in cancer vaccines at the Cancer Research UK Southampton Clinical Trials Unit which is based within the Centre for Cancer Immunology at the University of Southampton. We are looking forward to this amazing opportunity to work closely with our Australian research partners to investigate whether this cancer vaccine is of benefit to our UK and Australian colorectal patients. If we see evidence of activity and safety this would justify a future larger randomised trial which could change practice”.

Kerry-Ann Longman, Senior Trial Manager for the Neo-POLEM trial at the Southampton Clinical Trials Unit, said: “It is really exciting to see our first site opening in Australia and beginning to recruit patients into this groundbreaking trial. Neo-POLEM will accelerate patient access to innovative, new treatment vaccines and we are looking forward to opening the study in the UK in the coming months.”

Neo-POLEM is an international study conducted by Cancer Research UK Southampton Clinical Trials Unit in collaboration with Royal Surrey Hospital NHS Foundation Trust and the Australasian Gastro-Intestinal Trials Group (AGITG). The University of Southampton is the academic Sponsor of Neo-POLEM with AGITG is acting as the local sponsor, with the AGITG Clinical Research Centre as the coordinating centre and Professor Tim Price as the local study lead. Neo-POLEM is funded by clinical-stage immuno-oncology company, Imugene Limited.

Privacy Settings